Efficacy and safety of abatacept to treat active birdshot uveitis: a prospective open label interventional proof-of-concept trial
CONCLUSIONS: Abatacept is very efficacious to treat both retinal vasculitis and choroiditis in patients with BU and is well tolerated. BCVA and CRT are inadequate to monitor disease activity. On the other hand, CCT is a promising non-invasive tool to detect treatment response in early active BU and dual FA-ICGA Score is very helpful to evaluate retinal vasculitis and choroiditis quantitatively.TRIAL REGISTRATION NUMBER: NCT03871361.PMID:36585127 | DOI:10.1136/bjo-2022-321585 (Source: The British Journal of Ophthalmology)
Source: The British Journal of Ophthalmology - December 30, 2022 Category: Opthalmology Authors: P P Schauwvlieghe Joachim Van Calster Carl Peter Herbort Philippe A Kestelyn Kurt de Vlam Source Type: research
Efficacy and safety of abatacept to treat active birdshot uveitis: a prospective open label interventional proof-of-concept trial
CONCLUSIONS: Abatacept is very efficacious to treat both retinal vasculitis and choroiditis in patients with BU and is well tolerated. BCVA and CRT are inadequate to monitor disease activity. On the other hand, CCT is a promising non-invasive tool to detect treatment response in early active BU and dual FA-ICGA Score is very helpful to evaluate retinal vasculitis and choroiditis quantitatively.TRIAL REGISTRATION NUMBER: NCT03871361.PMID:36585127 | DOI:10.1136/bjo-2022-321585 (Source: The British Journal of Ophthalmology)
Source: The British Journal of Ophthalmology - December 30, 2022 Category: Opthalmology Authors: P P Schauwvlieghe Joachim Van Calster Carl Peter Herbort Philippe A Kestelyn Kurt de Vlam Source Type: research
Efficacy and safety of abatacept to treat active birdshot uveitis: a prospective open label interventional proof-of-concept trial
CONCLUSIONS: Abatacept is very efficacious to treat both retinal vasculitis and choroiditis in patients with BU and is well tolerated. BCVA and CRT are inadequate to monitor disease activity. On the other hand, CCT is a promising non-invasive tool to detect treatment response in early active BU and dual FA-ICGA Score is very helpful to evaluate retinal vasculitis and choroiditis quantitatively.TRIAL REGISTRATION NUMBER: NCT03871361.PMID:36585127 | DOI:10.1136/bjo-2022-321585 (Source: The British Journal of Ophthalmology)
Source: The British Journal of Ophthalmology - December 30, 2022 Category: Opthalmology Authors: P P Schauwvlieghe Joachim Van Calster Carl Peter Herbort Philippe A Kestelyn Kurt de Vlam Source Type: research
Genes, Vol. 14, Pages 89: The Yin-Yang Pharmacomicrobiomics on Treatment Response in Inflammatory Arthritides: A Narrative Review
Conclusions: Future improvement in pharmacomicrobiomics could help to detect an effective biomarker able to guide treatment choice and optimize management of inflammatory arthritides. (Source: Genes)
Source: Genes - December 28, 2022 Category: Genetics & Stem Cells Authors: Silvia Peretti Sara Torracchi Edda Russo Francesco Bonomi Elisa Fiorentini Khadija El Aoufy Cosimo Bruni Gemma Lepri Martina Orlandi Maria Sole Chimenti Serena Guiducci Amedeo Amedei Marco Matucci-Cerinic Silvia Bellando Randone Tags: Review Source Type: research
Case report: Challenges in immune reconstitution following hematopoietic stem cell transplantation for CTLA-4 insufficiency-like primary immune regulatory disorders
We present case 1 (CTLA-4 haploinsufficiency) and case 2 (CTLA-4 insufficiency-like phenotype) manifesting with severe autoimmunity including cytopenia and involvement of the central nervous system (CNS), lung, and gut and variable impairment of humoral responses. Both patients underwent HSCT for which the main complications were persistent mixed chimerism, infections, and immune-mediated complications [graft-versus-host disease (GVHD) and nodular lung disease]. Detailed management and outcomes of therapeutic interventions post-HSCT are discussed. Concretely, post-HSCT abatacept and human leukocyte antigen (HLA)-matched si...
Source: Frontiers in Immunology - December 27, 2022 Category: Allergy & Immunology Source Type: research
Risk of melanoma and nonmelanoma skin cancer with immunosuppressants Part II: Methotrexate, alkylating agents, biologics, and small molecule inhibitors
In solid organ transplant recipients, skin cancer risk associated with post-transplant immunosuppression has been well-described, and screening practices generally reflect these risks. In addition to agents used post-transplant, other classes of immunosuppressants also have the potential to raise the risk of nonmelanoma skin cancer (NMSC) or melanoma. In the present manuscript, the evidence for melanoma and NMSC risk associated with methotrexate, cyclophosphamide, biologic cytokine inhibitors including TNF-alpha and interleukin inhibitors, costimulation blockers such as abatacept, integrin inhibitors such as natalizumab, t...
Source: Journal of the American Academy of Dermatology - November 29, 2022 Category: Dermatology Authors: Margaret Ann Kreher, Sailesh Konda, Mary Margaret B. Noland, Maria I. Longo, Rodrigo Valdes-Rodriguez Source Type: research
Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part II: Methotrexate, alkylating agents, biologics, and small molecule inhibitors
In solid organ transplant recipients, skin cancer risk associated with posttransplant immunosuppression has been well-described, and screening practices generally reflect these risks. In addition to agents used posttransplant, other classes of immunosuppressants also have the potential to raise the risk of nonmelanoma skin cancer (NMSC) or melanoma. In the present manuscript, the evidence for melanoma and NMSC risk associated with methotrexate, cyclophosphamide, biologic cytokine inhibitors including TNF (tumor necrosis factor)-alpha and interleukin inhibitors, costimulation blockers such as abatacept, integrin inhibitors ...
Source: Journal of the American Academy of Dermatology - November 29, 2022 Category: Dermatology Authors: Margaret Ann Kreher, Sailesh Konda, Mary Margaret B. Noland, Maria I. Longo, Rodrigo Valdes-Rodriguez Tags: Continuing medical education Source Type: research
Potential Benefit of Rituximab in Rhupus Patients From a Single-Center: A Series of 16 Cases
Conclusions
In rhupus refractory to conventional treatment, T or B lymphocytes targeted therapies, and particularly rituximab, seem to be a relevant therapeutic option unlike anticytokine biologics. (Source: JCR: Journal of Clinical Rheumatology)
Source: JCR: Journal of Clinical Rheumatology - November 24, 2022 Category: Rheumatology Tags: Concise Report Source Type: research
Tocilizumab Attenuates Anti-neutrophil Cytoplasmic Antibody-associated Nephritis Occurring During Abatacept and Adalimumab Therapy for Rheumatoid Arthritis: A Case Report
Intern Med. 2022 Nov 23. doi: 10.2169/internalmedicine.0858-22. Online ahead of print.ABSTRACTWe encountered an 86-year-old Japanese woman who presented with proteinuria (0.4 g/day) and hematuria (red blood cell sediment >100/high-power field), a decreased renal function (serum creatinine, 1.51 mg/dL), and elevated myeloperoxidase anti-neutrophil cytoplasmic antibody (MPO-ANCA) levels (231 IU/mL) during treatment of rheumatoid arthritis with abatacept (a CTLA-4 agent) and adalimumab (a tumor necrosis factor-α agent). A kidney biopsy showed pauci-immune necrotizing glomerulonephritis, and ANCA-associated vasculitis was ...
Source: Internal Medicine - November 23, 2022 Category: Internal Medicine Authors: Yusuke Yoshimura Shun Watanabe Masayuki Yamanouchi Daisuke Ikuma Hiroki Mizuno Akinari Sekine Eiko Hasegawa Tatsuya Suwabe Kei Kono Keiichi Kinowaki Kenichi Ohashi Yoshifumi Ubara Naoki Sawa Source Type: research
Controversies and expectations for the prevention of GVHD: A biological and clinical perspective
Severe acute and chronic graft versus host disease (GVHD) remains a major cause of morbidity and mortality after allogeneic hematopoietic cell transplantation. Historically, cord blood and matched sibling transplantation has been associated with the lowest rates of GVHD. Newer methods have modified the lymphocyte components to minimize alloimmunity, including: anti-thymocyte globulin, post-transplant cyclophosphamide, alpha/beta T cell depletion, and abatacept. These agents have shown promise in reducing severe GVHD, however, can be associated with increased risks of relapse, graft failure, infections, and delayed immune r...
Source: Frontiers in Immunology - November 23, 2022 Category: Allergy & Immunology Source Type: research
